magnesium chloride Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	4200	7786-30-3

Description:

Molecule	Description
Synonyms: magnesium chloride	Magnesium chloride. An inorganic compound consisting of one magnesium and two chloride ions. The compound is used in medicine as a source of magnesium ions, which are essential for many cellular activities. It has also been used as a cathartic and in alloys. Molecular weight: 95.21 Formula: Cl2Mg CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Drug dosage:

Dose	Unit	Route
2.50	g	O
0.80	g	P

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Aug. 13, 1975	FDA	HOSPIRA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Death	5538.65	19.52	2883	23047	354349	52968787
Peritonitis bacterial	4174.81	19.52	958	24972	8547	53314589
Peritonitis	3435.78	19.52	968	24962	20719	53302417
Peritoneal dialysis complication	1709.26	19.52	371	25559	2462	53320674
Fluid overload	1319.45	19.52	499	25431	27332	53295804
Toxic anterior segment syndrome	753.03	19.52	184	25746	2164	53320972
Fungal peritonitis	580.71	19.52	125	25805	789	53322347
Sepsis	506.75	19.52	478	25452	145951	53177185
Ultrafiltration failure	497.63	19.52	104	25826	557	53322579
Bloody peritoneal effluent	461.43	19.52	93	25837	402	53322734
Myocardial infarction	327.29	19.52	316	25614	99038	53224098
Endophthalmitis	319.07	19.52	103	25827	3484	53319652
Abdominal distension	309.46	19.52	278	25652	79512	53243624
Cardiovascular disorder	284.72	19.52	133	25797	12280	53310856
Hypotension	281.31	19.52	468	25462	253608	53069528
Drug ineffective	272.55	19.52	38	25892	817207	52505929
Acute myocardial infarction	270.62	19.52	180	25750	33055	53290081
Catheter site infection	263.37	19.52	97	25833	4895	53318241
Procedural pain	263.19	19.52	133	25797	14584	53308552
Cardiac arrest	253.57	19.52	268	25662	93399	53229737
Cardiac disorder	248.84	19.52	196	25734	46770	53276366
Cardio-respiratory arrest	240.18	19.52	211	25719	58547	53264589
Peritoneal cloudy effluent	236.56	19.52	49	25881	249	53322887
Cerebrovascular accident	226.40	19.52	267	25663	104907	53218229
Diabetic foot	223.33	19.52	66	25864	1652	53321484
Hypopyon	175.37	19.52	48	25882	903	53322233
Disease complication	174.56	19.52	64	25866	3186	53319950
Corneal oedema	166.77	19.52	54	25876	1843	53321293
Cardiac failure	146.31	19.52	194	25736	85650	53237486
Multimorbidity	143.99	19.52	39	25891	704	53322432
Device interaction	141.18	19.52	31	25899	217	53322919
Hypervolaemia	136.29	19.52	48	25882	2125	53321011
Rheumatoid arthritis	124.70	19.52	7	25923	314524	53008612
Fatigue	119.71	19.52	108	25822	730398	52592738
Cardiac failure congestive	118.83	19.52	183	25747	92574	53230562
Encapsulating peritoneal sclerosis	115.58	19.52	29	25901	382	53322754
Dehydration	114.92	19.52	253	25677	168157	53154979
Gangrene	107.92	19.52	51	25879	4826	53318310
Diabetic complication	107.82	19.52	33	25897	933	53322203
Headache	107.73	19.52	64	25866	536757	52786379
Anterior chamber fibrin	106.82	19.52	24	25906	189	53322947
Hernia	104.39	19.52	64	25866	10196	53312940
Umbilical hernia	103.40	19.52	42	25888	2760	53320376
Noninfectious peritonitis	103.18	19.52	24	25906	224	53322912
Arthralgia	102.36	19.52	43	25887	439740	52883396
Inadequate aseptic technique in use of product	100.37	19.52	21	25909	113	53323023
Abdominal pain	98.15	19.52	310	25620	255593	53067543
Treatment noncompliance	93.65	19.52	97	25833	32938	53290198
Malnutrition	91.73	19.52	68	25862	14803	53308333
Drug interaction	86.51	19.52	5	25925	219324	53103812
Fluid imbalance	84.61	19.52	23	25907	421	53322715
Device related infection	79.61	19.52	75	25855	22711	53300425
Fluid retention	76.26	19.52	112	25818	54289	53268847
Pleuroperitoneal communication	74.56	19.52	15	25915	64	53323072
Joint swelling	73.01	19.52	13	25917	234625	53088511
Alopecia	72.99	19.52	13	25917	234570	53088566
Drug intolerance	71.85	19.52	8	25922	205485	53117651
Post procedural complication	70.31	19.52	61	25869	16605	53306531
Peritoneal effluent abnormal	69.54	19.52	14	25916	60	53323076
Pulmonary oedema	65.96	19.52	104	25826	53619	53269517
Toxicity to various agents	64.46	19.52	14	25916	219584	53103552
Anterior chamber cell	63.96	19.52	20	25910	608	53322528
Extremity necrosis	63.94	19.52	26	25904	1713	53321423
Marasmus	62.22	19.52	19	25911	533	53322603
Device occlusion	60.77	19.52	39	25891	6726	53316410
Infusion related reaction	60.13	19.52	4	25926	155953	53167183
Abdominal hernia	58.54	19.52	34	25896	4906	53318230
Anterior chamber inflammation	56.92	19.52	16	25914	333	53322803
Anterior chamber disorder	56.72	19.52	13	25917	113	53323023
Off label use	56.59	19.52	89	25841	472123	52851013
Azotaemia	55.98	19.52	32	25898	4481	53318655
Pneumoperitoneum	51.94	19.52	22	25908	1607	53321529
Calciphylaxis	51.42	19.52	26	25904	2849	53320287
Pneumonia	50.24	19.52	354	25576	406815	52916321
Completed suicide	49.26	19.52	5	25925	138196	53184940
Arthropathy	48.20	19.52	6	25924	141447	53181689
Treatment failure	47.49	19.52	4	25926	128399	53194737
Pain	47.12	19.52	139	25791	588259	52734877
Peritoneal disorder	45.60	19.52	15	25915	538	53322598
Hepatic enzyme increased	43.86	19.52	5	25925	126190	53196946
Aqueous fibrin	43.22	19.52	10	25920	91	53323045
Product use issue	42.81	19.52	8	25922	139576	53183560
Hypoglycaemia	41.67	19.52	90	25840	58923	53264213
Injection site pain	40.67	19.52	4	25926	113387	53209749
Wrong product administered	40.33	19.52	29	25901	6019	53317117
General physical health deterioration	39.82	19.52	159	25771	146783	53176353
Bacterial translocation	39.74	19.52	11	25919	216	53322920
Intestinal perforation	38.87	19.52	37	25893	11343	53311793
Maternal exposure during pregnancy	38.10	19.52	14	25916	155625	53167511
Dizziness	37.51	19.52	78	25852	372181	52950955
Procedural complication	37.09	19.52	26	25904	5186	53317950
Hypophagia	36.55	19.52	59	25871	31003	53292133
Acute kidney injury	36.26	19.52	42	25888	253826	53069310
Myalgia	36.24	19.52	10	25920	133481	53189655
Localised infection	35.98	19.52	54	25876	26662	53296474
Sinusitis	35.24	19.52	19	25911	168545	53154591
Anterior chamber flare	34.66	19.52	9	25921	137	53322999
Tonsillar haemorrhage	34.63	19.52	10	25920	230	53322906
Failure to thrive	34.46	19.52	28	25902	6964	53316172
Nasopharyngitis	34.29	19.52	26	25904	192269	53130867
Cataract operation complication	34.24	19.52	9	25921	144	53322992
Vitritis	33.96	19.52	14	25916	955	53322181
Somnolence	33.50	19.52	20	25910	167714	53155422
Hypersensitivity	33.27	19.52	32	25898	210633	53112503
Gait disturbance	33.06	19.52	18	25912	158824	53164312
Fibrin	32.67	19.52	7	25923	43	53323093
Insomnia	32.46	19.52	26	25904	187046	53136090
Paraesthesia	32.01	19.52	11	25919	127504	53195632
Pain in extremity	31.95	19.52	56	25874	284994	53038142
Eye inflammation	31.44	19.52	22	25908	4375	53318761
Product container issue	30.41	19.52	16	25914	1903	53321233
Infection	30.14	19.52	164	25766	172041	53151095
Depression	29.85	19.52	27	25903	183025	53140111
Overdose	29.37	19.52	8	25922	107728	53215408
Anxiety	28.66	19.52	32	25898	196672	53126464
Neutropenia	27.76	19.52	22	25908	159163	53163973
Exposure during pregnancy	27.70	19.52	13	25917	124847	53198289
Multiple organ dysfunction syndrome	27.55	19.52	74	25856	55603	53267533
Critical illness	27.46	19.52	8	25922	190	53322946
Asthenia	27.41	19.52	271	25659	343319	52979817
Exfoliative rash	27.27	19.52	17	25913	2787	53320349
Erythema	26.99	19.52	22	25908	156947	53166189
Hypertensive crisis	26.56	19.52	34	25896	14472	53308664
Systemic lupus erythematosus	26.40	19.52	14	25916	125400	53197736
Nosocomial infection	26.21	19.52	14	25916	1717	53321419
Metabolic alkalosis	26.12	19.52	17	25913	3002	53320134
Condition aggravated	25.31	19.52	68	25862	297066	53026070
Septic shock	25.24	19.52	77	25853	62152	53260984
Pyrexia	24.99	19.52	106	25824	403087	52920049
Hypoaesthesia	24.98	19.52	17	25913	132978	53190158
Blood glucose decreased	24.90	19.52	39	25891	19977	53303159
Injection site erythema	24.61	19.52	4	25926	77245	53245891
Blood potassium decreased	24.43	19.52	58	25872	40402	53282734
Pancytopenia	24.32	19.52	7	25923	90921	53232215
Peritoneal effluent leukocyte count increased	24.20	19.52	5	25925	25	53323111
Haemorrhagic stroke	24.13	19.52	21	25909	5737	53317399
Cough	24.05	19.52	56	25874	256837	53066299
Foreign body in eye	23.76	19.52	7	25923	173	53322963
Hydrothorax	23.47	19.52	10	25920	741	53322395
Post procedural infection	23.38	19.52	24	25906	8057	53315079
White blood cell count decreased	23.26	19.52	16	25914	124459	53198677
Febrile neutropenia	23.16	19.52	11	25919	104925	53218211
Intestinal ischaemia	23.01	19.52	23	25907	7479	53315657
Psoriasis	22.76	19.52	7	25923	87082	53236054
Mental status changes postoperative	22.54	19.52	7	25923	208	53322928
Intentional overdose	22.52	19.52	3	25927	67202	53255934
Therapy cessation	22.42	19.52	45	25885	27980	53295156
Staphylococcus test positive	22.30	19.52	17	25913	3856	53319280
Complication associated with device	22.23	19.52	33	25897	16132	53307004
Cardiac procedure complication	22.22	19.52	7	25923	218	53322918
Palpitations	22.18	19.52	11	25919	102337	53220799
Blood pressure decreased	21.85	19.52	73	25857	61796	53261340
Flushing	21.74	19.52	4	25926	70596	53252540
Osteoarthritis	21.69	19.52	4	25926	70482	53252654
Catheter site abscess	21.46	19.52	5	25925	47	53323089
Confusion postoperative	21.44	19.52	7	25923	245	53322891
Device leakage	21.20	19.52	20	25910	6060	53317076
Hip fracture	20.98	19.52	44	25886	28213	53294923
Renal transplant failure	20.80	19.52	9	25921	693	53322443
Escherichia peritonitis	20.09	19.52	4	25926	16	53323120
Blood glucose false positive	20.09	19.52	4	25926	16	53323120
Mental status changes	19.98	19.52	53	25877	39518	53283618
Oncologic complication	19.90	19.52	6	25924	161	53322975
Hospitalisation	19.87	19.52	5	25925	71007	53252129
Post procedural inflammation	19.78	19.52	5	25925	68	53323068
Catheter site extravasation	19.59	19.52	7	25923	323	53322813
Pancreatitis	19.56	19.52	58	25872	46084	53277052

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Death	5403.97	21.14	3697	27432	378820	32103577
Peritonitis bacterial	5195.49	21.14	1376	29753	11120	32471277
Peritonitis	3976.29	21.14	1273	29856	21057	32461340
Peritoneal dialysis complication	2338.44	21.14	587	30542	3681	32478716
Fluid overload	1664.52	21.14	646	30483	18975	32463422
Fungal peritonitis	773.14	21.14	195	30934	1241	32481156
Ultrafiltration failure	560.19	21.14	133	30996	630	32481767
Abdominal distension	462.86	21.14	387	30742	50908	32431489
Toxic anterior segment syndrome	448.17	21.14	130	30999	1482	32480915
Bloody peritoneal effluent	395.51	21.14	95	31034	477	32481920
Cardiac disorder	379.86	21.14	317	30812	41549	32440848
Catheter site infection	371.85	21.14	128	31001	2626	32479771
Myocardial infarction	371.41	21.14	525	30604	125151	32357246
Procedural pain	353.17	21.14	148	30981	5281	32477116
Sepsis	348.78	21.14	578	30551	158256	32324141
Cardiac arrest	321.42	21.14	428	30701	96348	32386049
Peritoneal cloudy effluent	307.17	21.14	74	31055	377	32482020
Cardiovascular disorder	259.66	21.14	149	30980	10613	32471784
Drug ineffective	256.45	21.14	33	31096	383444	32098953
Diabetic foot	242.70	21.14	95	31034	2831	32479566
Cardiac failure	237.07	21.14	360	30769	91313	32391084
Hernia	227.57	21.14	131	30998	9384	32473013
Multimorbidity	194.23	21.14	54	31075	521	32481876
Fluid retention	192.28	21.14	177	30952	26373	32456024
Cardio-respiratory arrest	189.18	21.14	250	30879	55739	32426658
Inguinal hernia	186.22	21.14	108	31021	7844	32474553
Acute kidney injury	178.29	21.14	33	31096	293435	32188962
Acute myocardial infarction	178.28	21.14	241	30888	54908	32427489
Endophthalmitis	174.18	21.14	82	31047	3867	32478530
Noninfectious peritonitis	155.28	21.14	38	31091	209	32482188
Hypotension	151.26	21.14	502	30627	215608	32266789
Hypervolaemia	146.97	21.14	64	31065	2510	32479887
Off label use	145.46	21.14	56	31073	306264	32176133
Drug interaction	144.93	21.14	19	31110	218166	32264231
Toxicity to various agents	144.82	21.14	6	31123	178035	32304362
Gangrene	140.70	21.14	76	31053	4806	32477591
Inadequate aseptic technique in use of product	140.24	21.14	33	31096	149	32482248
Diabetic complication	136.28	21.14	46	31083	886	32481511
Fluid imbalance	133.18	21.14	38	31091	406	32481991
Fatigue	128.25	21.14	90	31039	350611	32131786
Peritoneal disorder	125.81	21.14	36	31093	389	32482008
Device related infection	124.86	21.14	117	31012	17816	32464581
Umbilical hernia	124.52	21.14	67	31062	4203	32478194
Cerebrovascular accident	123.46	21.14	262	30867	86058	32396339
Azotaemia	117.94	21.14	70	31059	5304	32477093
Dehydration	115.63	21.14	327	30802	128631	32353766
Peritoneal effluent abnormal	113.15	21.14	27	31102	131	32482266
Disease complication	107.19	21.14	53	31076	2786	32479611
Encapsulating peritoneal sclerosis	105.08	21.14	35	31094	646	32481751
Localised infection	99.84	21.14	96	31033	15091	32467306
Device interaction	94.42	21.14	31	31098	546	32481851
Treatment noncompliance	92.59	21.14	122	31007	27080	32455317
Headache	87.89	21.14	39	31090	196158	32286239
Cardiac failure congestive	87.84	21.14	227	30902	84625	32397772
Post procedural complication	85.41	21.14	79	31050	11828	32470569
Neutropenia	74.24	21.14	22	31107	142153	32340244
Hypopyon	73.75	21.14	25	31104	488	32481909
Dizziness	71.02	21.14	58	31071	209560	32272837
Corneal oedema	70.06	21.14	32	31097	1406	32480991
Abdominal pain	69.27	21.14	305	30824	149224	32333173
Somnolence	66.54	21.14	10	31119	103787	32378610
Completed suicide	66.53	21.14	6	31123	92511	32389886
Drug abuse	64.19	21.14	3	31126	80240	32402157
Thrombocytopenia	62.50	21.14	32	31097	148267	32334130
Product use in unapproved indication	61.79	21.14	6	31123	87198	32395199
Platelet count decreased	61.15	21.14	17	31112	114574	32367823
Device occlusion	60.14	21.14	51	31078	6807	32475590
Arthralgia	59.68	21.14	34	31095	148414	32333983
Complication associated with device	59.17	21.14	48	31081	6024	32476373
Overdose	59.12	21.14	7	31122	87070	32395327
Febrile neutropenia	58.00	21.14	21	31108	119545	32362852
Pancytopenia	57.99	21.14	9	31120	91226	32391171
White blood cell count decreased	55.74	21.14	10	31119	91188	32391209
Anterior chamber fibrin	55.28	21.14	15	31114	131	32482266
Failure to thrive	54.82	21.14	53	31076	8382	32474015
Disease progression	54.24	21.14	9	31120	86853	32395544
Extremity necrosis	53.86	21.14	29	31100	1821	32480576
Anterior chamber cell	51.26	21.14	18	31111	392	32482005
Anxiety	49.82	21.14	15	31114	95990	32386407
Myalgia	47.33	21.14	10	31119	81220	32401177
Marasmus	46.90	21.14	19	31110	620	32481777
Cardiac procedure complication	46.79	21.14	15	31114	244	32482153
Infection	46.37	21.14	182	30947	84533	32397864
Swelling	45.56	21.14	108	31021	38114	32444283
Pulmonary oedema	44.98	21.14	121	31008	46146	32436251
Calciphylaxis	44.18	21.14	22	31107	1174	32481223
Abdominal discomfort	43.71	21.14	130	30999	52494	32429903
Hip fracture	43.10	21.14	55	31074	11820	32470577
Alanine aminotransferase increased	43.07	21.14	11	31118	78468	32403929
Postoperative wound infection	42.95	21.14	36	31093	4728	32477669
Nausea	42.52	21.14	161	30968	320688	32161709
Pyrexia	42.11	21.14	161	30968	319807	32162590
Renal impairment	40.00	21.14	19	31110	91953	32390444
Abdominal hernia	39.56	21.14	28	31101	2865	32479532
Foreign body in eye	39.03	21.14	11	31118	112	32482285
Pleuroperitoneal communication	38.18	21.14	9	31120	41	32482356
Rhabdomyolysis	37.74	21.14	9	31120	67256	32415141
Mycobacterial peritonitis	37.32	21.14	9	31120	46	32482351
Anaemia	35.93	21.14	103	31026	223521	32258876
Diarrhoea	35.92	21.14	204	30925	364598	32117799
Hydrothorax	35.90	21.14	15	31114	530	32481867
Leukopenia	35.85	21.14	7	31122	60115	32422282
Agitation	35.57	21.14	6	31123	57230	32425167
Depression	35.18	21.14	25	31104	97035	32385362
Aspartate aminotransferase increased	35.15	21.14	10	31119	66419	32415978
Insomnia	34.88	21.14	27	31102	100321	32382076
Neuropathy peripheral	34.88	21.14	15	31114	76967	32405430
Malignant neoplasm progression	34.46	21.14	16	31113	78480	32403917
Procedural complication	33.34	21.14	31	31098	4669	32477728
Psoriasis	33.12	21.14	3	31126	46120	32436277
Staphylococcus test positive	32.93	21.14	26	31103	3139	32479258
Malnutrition	32.42	21.14	49	31080	12329	32470068
Eye inflammation	32.06	21.14	21	31108	1892	32480505
Pneumonia	32.03	21.14	497	30632	354755	32127642
Erythema	32.01	21.14	20	31109	83085	32399312
Cataract operation complication	32.00	21.14	10	31119	149	32482248
Tachycardia	31.91	21.14	18	31111	79070	32403327
Rheumatoid arthritis	31.71	21.14	3	31126	44541	32437856
Neutrophil count decreased	31.47	21.14	4	31125	47135	32435262
Gait disturbance	31.45	21.14	19	31110	80389	32402008
Asthma	31.28	21.14	3	31126	44062	32438335
Discomfort	31.01	21.14	55	31074	15800	32466597
Inappropriate schedule of product administration	30.32	21.14	4	31125	45821	32436576
Peritoneal effluent leukocyte count increased	30.04	21.14	7	31122	30	32482367
Blood creatine phosphokinase increased	30.02	21.14	4	31125	45472	32436925
Pulmonary embolism	29.72	21.14	22	31107	83637	32398760
Interstitial lung disease	28.92	21.14	13	31116	64988	32417409
Diabetic vascular disorder	28.69	21.14	8	31121	78	32482319
Fibrin	28.68	21.14	7	31122	38	32482359
Peripheral vascular disorder	28.53	21.14	30	31099	5242	32477155
Blood creatinine increased	28.47	21.14	30	31099	96102	32386295
Corneal opacity	28.46	21.14	13	31116	571	32481826
Diabetic ulcer	28.45	21.14	9	31120	140	32482257
General physical health deterioration	28.23	21.14	198	30931	115061	32367336
Infusion related reaction	27.85	21.14	5	31124	45594	32436803
Cough	27.74	21.14	57	31072	138760	32343637
Aggression	27.14	21.14	3	31126	39386	32443011
Musculoskeletal stiffness	27.03	21.14	3	31126	39261	32443136
Hydrocele	26.93	21.14	20	31109	2204	32480193
Dyspnoea exertional	26.76	21.14	3	31126	38958	32443439
Product container issue	26.34	21.14	14	31115	856	32481541
Nosocomial infection	26.28	21.14	16	31113	1269	32481128
Bacterial translocation	26.22	21.14	10	31119	277	32482120
Drug intolerance	25.77	21.14	8	31121	50227	32432170
Chest pain	25.72	21.14	205	30924	123932	32358465
Road traffic accident	25.06	21.14	53	31076	17328	32465069
Vitritis	24.86	21.14	13	31116	769	32481628
Scrotal swelling	24.85	21.14	16	31113	1400	32480997
International normalised ratio increased	24.82	21.14	8	31121	49027	32433370
Corneal infiltrates	24.46	21.14	9	31120	225	32482172
Product use issue	24.36	21.14	10	31119	52767	32429630
Blood pressure abnormal	24.25	21.14	33	31096	7547	32474850
Hallucination	24.24	21.14	10	31119	52609	32429788
Foetal exposure during pregnancy	24.22	21.14	5	31124	41296	32441101
Blood glucose decreased	24.00	21.14	45	31084	13489	32468908
Post procedural infection	23.73	21.14	26	31103	4759	32477638
Hepatic function abnormal	23.26	21.14	7	31122	44833	32437564
Hospitalisation	23.05	21.14	9	31120	48962	32433435
Paraesthesia	22.95	21.14	14	31115	58930	32423467
Skin exfoliation	22.66	21.14	64	31065	25093	32457304
Blood glucose false positive	22.58	21.14	6	31123	48	32482349
Oxygen saturation decreased	22.38	21.14	9	31120	48090	32434307
Blood bilirubin increased	22.12	21.14	5	31124	38779	32443618
Pain	21.73	21.14	99	31030	187457	32294940
Intestinal perforation	21.65	21.14	34	31095	8841	32473556
Withdrawal of life support	21.54	21.14	5	31124	21	32482376
Anterior chamber disorder	21.49	21.14	7	31122	120	32482277
Coronary artery occlusion	21.38	21.14	39	31090	11446	32470951
Stomatitis	21.38	21.14	6	31123	40223	32442174
Tremor	21.24	21.14	28	31101	81249	32401148
Aqueous fibrin	21.21	21.14	6	31123	62	32482335
Intentional product use issue	21.16	21.14	7	31122	42204	32440193

Pharmacologic Action:

Source	Code	Description
ATC	A12CC01	ALIMENTARY TRACT AND METABOLISM MINERAL SUPPLEMENTS OTHER MINERAL SUPPLEMENTS Magnesium
ATC	B05XA11	BLOOD AND BLOOD FORMING ORGANS BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS I.V. SOLUTION ADDITIVES Electrolyte solutions

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Hypomagnesemia	indication	190855004
Anuria	contraindication	2472002	DOID:2983
Hypocalcemia	contraindication	5291005
Classical phenylketonuria	contraindication	7573000
Poisoning by digitalis glycoside	contraindication	12876009
Hyperkalemia	contraindication	14140009
Complete atrioventricular block	contraindication	27885002
Sarcoidosis	contraindication	31541009	DOID:11335
End stage renal disease	contraindication	46177005	DOID:784
Humoral hypercalcemia of malignancy	contraindication	47709007
Heart disease	contraindication	56265001	DOID:114
Congenital myotonia, autosomal dominant form	contraindication	57938005
Acute nephropathy	contraindication	58574008
Diarrhea	contraindication	62315008
Hypercalcemia	contraindication	66931009	DOID:12678
Hypermagnesemia	contraindication	66978005
Ventricular fibrillation	contraindication	71908006
Hypercalciuria	contraindication	71938000
Hyperchloremia	contraindication	74450001
Third degree burn injury	contraindication	80247002
Oliguria	contraindication	83128009
Kidney disease	contraindication	90708001	DOID:557
Kidney stone	contraindication	95570007
Hyporeninemic hypoaldosteronism	contraindication	236464008
Familial hyperkalemic periodic paralysis	contraindication	304737009	DOID:14451
Azotemia	contraindication	445009001
Severe dehydration	contraindication	450316000

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
0.21GM/100ML;2.8GM/100ML;9.07GM/100ML	NORMOCARB HF 25	DIALYSIS SUPS	N021910	July 26, 2006	RX	SOLUTION	INJECTION	7300674	March 4, 2023	USE AS REPLACEMENT SOLUTION, HEMOFILTRATION SOLUTION OR HEMODIAFILTRATION SOLUTION IN CONTINUOUS RENAL REPLACEMENT THERAPY

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
3.68GM/1000ML;3.05GM/1000ML;0.314GM/1000ML ;3.09GM/1000ML;6.34GM/1000ML;0.187GM/1000ML (5000ML)	PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER	BAXTER HLTHCARE CORP	N207026	Jan. 13, 2015	RX	INJECTABLE	INJECTION	Jan. 13, 2022	AS A REPLACEMENT SOLUTION IN CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT) AND IN CASE OF DRUG POISONING WHEN CRRT IS USED TO REMOVE DIALYZABLE SUBSTANCES
N/A/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;6.95GM/1000ML;0.187GM/1000ML (5000ML)	PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER	BAXTER HLTHCARE CORP	N207026	Jan. 13, 2015	RX	INJECTABLE	INJECTION	Jan. 13, 2022	AS A REPLACEMENT SOLUTION IN CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT) AND IN CASE OF DRUG POISONING WHEN CRRT IS USED TO REMOVE DIALYZABLE SUBSTANCES

Bioactivity Summary:

None

External reference:

ID	Source
4018213	VUID
N0000146546	NUI
D04834	KEGG_DRUG
4018213	VANDF
C0024472	UMLSCUI
CHEBI:86345	CHEBI
CHEMBL2219642	ChEMBL_ID
CHEMBL3185229	ChEMBL_ID
D015636	MESH_DESCRIPTOR_UI
DB09407	DRUGBANK_ID
7791-18-6	SECONDARY_CAS_RN
02F3473H9O	UNII
46835706	PUBCHEM_CID
6579	RXNORM
5007	MMSL
5009	MMSL
71973	MMSL
d03796	MMSL
000786	NDDF
45733002	SNOMEDCT_US
768454005	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
BSS	HUMAN PRESCRIPTION DRUG LABEL	6	0065-0795	SOLUTION	0.30 mg	OPHTHALMIC	NDA	9 sections
BSS	HUMAN PRESCRIPTION DRUG LABEL	6	0065-0795	SOLUTION	0.30 mg	OPHTHALMIC	NDA	9 sections
BSS	HUMAN PRESCRIPTION DRUG LABEL	6	0065-1795	SOLUTION	0.30 mg	OPHTHALMIC	NDA	9 sections
HyperlyteCR	HUMAN PRESCRIPTION DRUG LABEL	5	0264-1943	INJECTION, SOLUTION, CONCENTRATE	0.51 g	INTRAVENOUS	UNAPPROVED DRUG OTHER	18 sections
HyperlyteCR	HUMAN PRESCRIPTION DRUG LABEL	5	0264-1943	INJECTION, SOLUTION, CONCENTRATE	0.51 g	INTRAVENOUS	UNAPPROVED DRUG OTHER	18 sections
Balanced Salt	HUMAN PRESCRIPTION DRUG LABEL	6	0264-1945	SOLUTION	0.30 mg	IRRIGATION	ANDA	11 sections
Physiolyte	HUMAN PRESCRIPTION DRUG LABEL	5	0264-2205	IRRIGANT	0.03 g	IRRIGATION	NDA	20 sections
Physiolyte	HUMAN PRESCRIPTION DRUG LABEL	5	0264-2205	IRRIGANT	0.03 g	IRRIGATION	NDA	20 sections
Balanced Salt	HUMAN PRESCRIPTION DRUG LABEL	6	0264-2514	SOLUTION	0.30 mg	IRRIGATION	ANDA	11 sections
Isolyte S	HUMAN PRESCRIPTION DRUG LABEL	5	0264-7703	INJECTION, SOLUTION	0.03 g	INTRAVENOUS	NDA	19 sections
Isolyte S	HUMAN PRESCRIPTION DRUG LABEL	5	0264-7703	INJECTION, SOLUTION	0.03 g	INTRAVENOUS	NDA	19 sections
Isolyte S pH 7.4	HUMAN PRESCRIPTION DRUG LABEL	7	0264-7707	INJECTION, SOLUTION	0.03 g	INTRAVENOUS	NDA	24 sections
Isolyte S pH 7.4	HUMAN PRESCRIPTION DRUG LABEL	7	0264-7707	INJECTION, SOLUTION	0.03 g	INTRAVENOUS	NDA	24 sections
Isolyte P in Dextrose	HUMAN PRESCRIPTION DRUG LABEL	5	0264-7730	INJECTION, SOLUTION	0.03 g	INTRAVENOUS	NDA	23 sections
Isolyte P in Dextrose	HUMAN PRESCRIPTION DRUG LABEL	5	0264-7730	INJECTION, SOLUTION	0.03 g	INTRAVENOUS	NDA	23 sections
Dextrose and Electrolyte No. 48	HUMAN PRESCRIPTION DRUG LABEL	6	0338-0143	INJECTION	31 mg	INTRAVENOUS	NDA	19 sections
Dextrose and Electrolyte No. 48	HUMAN PRESCRIPTION DRUG LABEL	6	0338-0143	INJECTION	31 mg	INTRAVENOUS	NDA	19 sections
Plasma-Lyte 148	HUMAN PRESCRIPTION DRUG LABEL	5	0338-0179	INJECTION, SOLUTION	30 mg	INTRAVENOUS	NDA	20 sections
Plasma-Lyte 148	HUMAN PRESCRIPTION DRUG LABEL	5	0338-0179	INJECTION, SOLUTION	30 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0202	INJECTION	51 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0202	INJECTION	51 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0206	INJECTION	51 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0206	INJECTION	51 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0210	INJECTION	51 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0210	INJECTION	51 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0214	INJECTION	51 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0214	INJECTION	51 mg	INTRAVENOUS	NDA	20 sections
Plasma-Lyte A	HUMAN PRESCRIPTION DRUG LABEL	5	0338-0221	INJECTION, SOLUTION	30 mg	INTRAVENOUS	NDA	19 sections
Plasma-Lyte A	HUMAN PRESCRIPTION DRUG LABEL	5	0338-0221	INJECTION, SOLUTION	30 mg	INTRAVENOUS	NDA	19 sections
Cardioplegic	HUMAN PRESCRIPTION DRUG LABEL	4	0338-0341	SOLUTION	325.30 mg	INTRA-ARTERIAL	ANDA	15 sections